Institutional shares held 61.9 Million
243K calls
300K puts
Total value of holdings $2.63B
$10.3M calls
$12.7M puts
Market Cap $1.93B
45,878,200 Shares Out.
Institutional ownership 134.96%
# of Institutions 200


Latest Institutional Activity in MRUS

Top Purchases

Q3 2024
Lynx1 Capital Management LP Shares Held: 1.79M ($75.5M)
Q3 2024
Wellington Management Group LLP Shares Held: 2.89M ($122M)
Q3 2024
Siren, L.L.C. Shares Held: 682K ($28.7M)
Q3 2024
Deerfield Management Company, L.P. (Series C) Shares Held: 3.41M ($143M)
Q3 2024
Westfield Capital Management CO LP Shares Held: 608K ($25.6M)

Top Sells

Q3 2024
Janus Henderson Group PLC Shares Held: 18.9K ($795K)
Q3 2024
Adage Capital Partners Gp, L.L.C. Shares Held: 185K ($7.79M)
Q3 2024
Federated Hermes, Inc. Shares Held: 2.01M ($84.5M)
Q3 2024
Vr Adviser, LLC Shares Held: 908K ($38.2M)
Q3 2024
Logos Global Management LP Shares Held: 575K ($24.2M)

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.


Insider Transactions at MRUS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
114K Shares
From 2 Insiders
Exercise of conversion of derivative security 114K shares
Sell / Disposition
114K Shares
From 2 Insiders
Open market or private sale 114K shares

Track Institutional and Insider Activities on MRUS

Follow Merus N.V. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MRUS shares.

Notify only if

Insider Trading

Get notified when an Merus N.V. insider buys or sells MRUS shares.

Notify only if

News

Receive news related to Merus N.V.

Track Activities on MRUS